Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Oficina francesa de transferencia de tecnología ofrece un nuevo tratamiento de tumores sólidos para atacar células madre cancerosas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20180129001
Publicado:
26/02/2018
Caducidad:
27/02/2019
Resumen:
Una oficina francesa de transferencia de tecnología representa a un laboratorio de investigación de la región parisina que ha desarrollado un nuevo compuesto activo para reducir significativamente la actividad de las células madre cancerosas dentro de tumores sólidos. Este compuesto activo tiene un impacto eficiente en la reducción del crecimiento de tumores cerebrales sólidos (iniciación o recaída). La oficina de transferencia de tecnología busca compañías farmacéuticas o biotecnológicas con el fin de establecer acuerdos de licencia o cooperación técnica, así como centros de I+D que trabajen en investigación oncológica para alcanzar una cooperación en materia de investigación.

Details

Tittle:
French Technology Transfer Office offers new solid cancer treatment targeting cancer stem-cells
Summary:
A French Technology Transfer Office (TTO) offers an innovative treatment targeting solid tumors. The innovation is based on a specified and patented hit molecule which strongly reduces the activity of CSCs (Cancer Stem-like Cells).
The french TTO is looking for interested pharmacology corporates or biotechnology SMEs, either for a licensing agreement or a technical cooperation agreement. Research cooperation agreement is also open with R-Y-D institutions working in oncology research.
Description:
A French TTO acting on behalf major life science research labs in Paris Region, has developed a new patented hit molecule which strongly reduces the activity of the CSCs within solid tumors. CSCs are specific cells with self-renewal capacities whose no signaling pathway has been identified and used up to now.

State-of-the-art of solid cancer treatments :
CSCs activity is known to be a significant factor in solid cancer initiation and growth. Among all therapies, none has been proved to be efficient in reducing CSCs activity. A life-science research lab has identified a signaling pathway which is specific to the self-renewal properties of the CSCs.

Current stage of the technology :
A new hit molecule which inhibites a cell surface receptor of the above-mentioned specific signaling pathway in the CSCs, has been identified in glioblastoma.
The proof of concept of such inhibition using this new hit molecule has been done ex vivo and in vivo using several xenografted mice. A PCT patent has been applied in 2015.
Other mice models are investigated.
Batching and safety studies are in progress.

Requested partnership :
A licensing agreement is open to manufacturing drug corporates which are able to drive clinical testing of the new hit molecule, prior to its manufacturing and commercialization.
A technical cooperation agreement may also interest companies in biotechnology which are interested to work with the French research team in order to extend the pre-clinical trials to other animal models.
A research cooperation is open to R-Y-D institutions operating in oncology research, in order to improve the knowledge in targeting cancer stem-like cells with a view to find new means for solid cancer treatment.
Advantages and Innovations:
The newly found hit molecule has got competitive advantages since it offers the first efficient treatment for glioblastoma which targets cancer stem-like cells, strongly implicated in tumor initiation and therapeutic resistance.

First, the new hit molecule have an efficient impact in reducing solid brain cancer growth (initiation or relapse).

Secondly, the new hit molecule cuts through solid brain cancer radiotherapy and up-to-now chemotherapy resistance.

Finally, because the signaling pathway is specific to the self-renewal properties of the CSCs, it gives opportunities for potential treatment for other solid tumors.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
PCT patent application

Partner sought

Type and Role of Partner Sought:
The Technology Transfer Office is looking for Licensing or a technical cooperation agreement with :
- national or multinational corporates of drugs market and pharmacology business,
- Small and Medium-sized companies, startups, acting on biotechnology markety
Research cooperation agreement is also open to discussion with any R-Y-D institution working in the field of oncology research.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06002007 Ensayos in vitro, experimentos
06001002 Investigaciones clínicas, ensayos
06001019 Tecnologías de células madre